UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 8-K

CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): August 17, 2020

MICROBOT MEDICAL INC.
(Exact name of registrant as specified in its charter)

Delaware	**000-19871**	**94-3078125**
(State or other jurisdiction of incorporation)	**(Commission File Number)**	**(IRS Employer Identification No.)**

25 Recreation Park Drive, Unit 108
Hingham, Massachusetts 02043
(Address of Principal Executive Offices) (Zip Code)

Registrant's telephone number, including area code: (781) 875-3605

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

[ ] Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

[ ] Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

[ ] Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

[ ] Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	**Trading Symbol(s)**	**Name of each exchange on which registered**
Common Stock, $0.01 par value	MBOT	NASDAQ Capital Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).

Emerging Growth Company [ ]

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. [ ]

Item 7.01 Regulation FD Disclosure.

On August 17, 2020, Microbot Medical Inc. (the "Company") (a) issued a press release announcing and (b) posted presentation materials on its website with respect to, among other things, the results of a feasibility animal study performed using the Company's LIBERTY™ Robotic System.

The Company is attending the Needham Virtual Med Tech and Diagnostics Conference on August 17, 2020, where it will share the initial results.

The presentation materials can be accessed via the 'Investors' section, under 'Presentation + Resources,' of the Company's website at www.microbotmedical.com. The Company is not undertaking to update these presentation materials.

The press release and presentation materials furnished as Exhibit 99.1 and Exhibit 99.2, respectively, to this Current Report on Form 8-K are incorporated herein by reference. The information in this report (including Exhibits 99.1 and 99.2) is being furnished pursuant to Item 7.01 and shall not be deemed to be "filed" for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section. This report will not be deemed an admission as to the materiality of any information herein (including Exhibits 99.1 and 99.2).

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits

Exhibit Number	Description
99.1	Press Release
99.2	Presentation Materials

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

MICROBOT MEDICAL INC.

By: */s/ Harel Gadot*
Name: Harel Gadot
Title: Chief Executive Officer, President and Chairman

Date: August 17, 2020

Exhibit 99.1

Microbot Medical Announces Successful Animal Study Utilizing Its LIBERTY™ Robotic System

World's First Fully Disposable Surgical Robot Achieved all Endpoints with No Intraoperative Adverse Events

Remotely Performed Procedures have the Potential to Reduce Radiation Exposure, Physical Strain and Cross Contamination to Both the Patients and the Surgical Staff

HINGHAM, Mass., August 17, 2020 – Microbot Medical Inc. (Nasdaq: MBOT), today announced the successful conclusion of its feasibility animal study using the Company's LIBERTY™ Robotic System, the world's first fully disposable surgical robotic system. The study met all of its end points with no intraoperative adverse events, which supports the Company's objectives to allow physicians to conduct a catheter-based procedure from outside the catheterization laboratory (cath-lab), avoiding radiation exposure, physical strain and the risk of cross contamination. It was performed by two leading physicians in the neuro vascular and peripheral vascular intervention spaces, and the results demonstrated robust navigation capabilities, intuitive usability and accurate deployment of embolic agents, most of which was conducted remotely from the cath-lab's control room.

"We continue to validate the LIBERTY™ Robotic System and confirm our assertion that it has the potential to revolutionize the robotic surgery space by democratizing endoluminal procedures with enhanced clinical and economical outcomes," commented Harel Gadot, CEO, President and Chairman. "The freedom from capital equipment, coupled with the ability to operate LIBERTY™ remotely, especially in today's COVID-19 healthcare environment, will potentially reduce the cross contamination between the surgical staff and patients on top of reducing radiation exposure. Overall, we believe that we are in the right market, at the right time and with the right solution."

Mr. Gadot, along with other members of the management team, will be sharing these results at the Needham Virtual Med Tech & Diagnostics Conference being held today. A copy of the investor presentation, which highlights the initial results of the feasibility animal study, can be accessed via the 'Investors' section, under 'Presentation + Resources' of the Company's website at www.microbotmedical.com.

The Company believes that the LIBERTY^{TM} Robotic System, which was unveiled in January 2020, is the world's first fully disposable robotic system which features a unique compact design; With the capability to be operated remotely, it is being designed to reduce radiation exposure, the physical strain to the physician as well as cross contamination between the surgical staff and patients. In addition, incorporating the technology the Company acquired from CardioSert into the LIBERTY^{TM} Robotic System, has the potential to eliminate the use of multiple consumables through its "One & Done" capabilities.

About Microbot Medical

Microbot Medical Inc. (NASDAQ: MBOT) is a pre-clinical medical device company that specializes in transformational micro-robotic technologies, focused primarily on both natural and artificial lumens within the human body. Microbot's current proprietary technological platforms provide the foundation for the development of a Multi Generation Pipeline Portfolio (MGPP).

Microbot Medical was founded in 2010 by Harel Gadot, Prof. Moshe Shoham, and Yossi Bornstein with the goals of improving clinical outcomes for patients and increasing accessibility through the use of micro-robotic technologies. Further information about Microbot Medical is available at http://www.microbotmedical.com.

Safe Harbor

Statements pertaining to the registered direct offering, timing, the amount and anticipated use of proceeds and statements pertaining to future financial and/or operating results, future growth in research, technology, clinical development, and potential opportunities for Microbot Medical Inc. and its subsidiaries, along with other statements about the future expectations, beliefs, goals, plans, or prospects expressed by management, constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and the Federal securities laws. Any statements that are not historical fact (including, but not limited to statements that contain words such as "will," "believes," "plans," "anticipates," "expects" and "estimates") should also be considered to be forward-looking statements. Forward-looking statements involve risks and uncertainties, including, without limitation, market conditions and the satisfaction of customary closing conditions, risks inherent in the development and/or commercialization of potential products, including LIBERTY^{TM}, the outcome of its studies to evaluate the SCS and other existing and future technologies, uncertainty in the results of pre-clinical and clinical trials or regulatory pathways and regulatory approvals, uncertainty resulting from the COVID-19 pandemic, need and ability to obtain future capital, and maintenance of intellectual property rights. Additional information on risks facing Microbot Medical can be found under the heading "Risk Factors" in Microbot Medical's periodic reports filed with the Securities and Exchange Commission (SEC) and in the prospectus supplement related to the registered direct offering to be filed with the SEC, which are or will be available on the SEC's web site at www.sec.gov. Microbot Medical disclaims any intent or obligation to update these forward-looking statements, except as required by law.

Investor Contact:

Michael Polyviou
EVC Group
mpolyviou@evcgroup.com
732-933-2754

Exhibit 99.2

microbot medical

SAFE HARBOR STATEMENT

This document contains forward-looking statements within the meaning of Section 27A of the Securities Act and Section 21E of the Securities Exchange Act of 1934, as amended, relating to future events or the future financial performance and operations of Microbot. Forward-looking statements, which involve assumptions and describe Microbot's intent, belief or current expectations about its business opportunities, prospects, performance and results, are generally identifiable by use of the words "may," "could," "should," "will," "would," "expect," "anticipate," "plan," "potential," "estimate," "believe," "intend," "project," "forecast," the negative of such words and other variations on such words or similar terminology. All statements other than statements of historical fact could be deemed forward-looking statements, including, but not limited to: risks inherent in the development and/or commercialization of potential products, including LIBERTY; the outcome of our studies to evaluate the SCS and other existing and future technologies; uncertainty in the results of pre-clinical and clinical trials or regulatory pathways and regulatory approvals; uncertainty resulting from the COVID-19 pandemic; need and ability to obtain future capital; maintenance of intellectual property rights; our ability to find and develop applications for our technologies for other neurosurgical conditions besides hydrocephalus; our clinical development and other research and development plans and expectations; the safety and efficacy of our product candidates; the anticipated regulatory pathways for our product candidates; our ability to successfully complete preclinical and clinical development of, and obtain regulatory approval of our product candidates and commercialize any approved products on our expected timeframes or at all; the content and timing of submissions to and decisions made by the U.S. Food and Drug Administration and other regulatory agencies; our ability to leverage the experience of our management team; and any statements or assumptions underlying any of the items mentioned. These forward-looking statements are not guarantees of future performance and by their nature involve known and unknown risks and uncertainties that may cause actual opportunities, prospects, performance and results to vary from those presented in this document, and those variances may be material. In evaluating such statements, prospective investors should carefully consider the various risks and uncertainties identified in Microbot's public filings with the Securities and Exchange Commission (the "SEC"), such as market risk, liquidity risk, competitive risk, regulatory risk and other commonly recognized forms of risk relating to Microbot and its securities. In light of these risks, uncertainties and assumptions, the forward-looking events discussed in this document might not occur. Microbot is not obligated to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

This presentation shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of Microbot's securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or other jurisdiction.

MEDICAL ROBOTICS MARKET IS RAPIDLY GROWING

Minimally Invasive Surgery (MIS) is the fastest growing healthcare segment
>$50B

Expected
>20% CAGR
through 2025

Applies to
Most Surgical Specialties

Becoming
Smaller, Automated, and More Precise

SURGICAL ROBOTICS GROWTH OPPORTUNITY

U.S. Market for Surgical Robotics

Microbot Medical is in the Right Market, at the Right Time with the Right Products!

HEALTHCARE LANDSCAPE
POSITIONED FOR POST COVID-19

- Telehealth has been a core focus of Microbot's product development roadmap
- LIBERTY and SCS are designed to be remote controlled and monitored

Cardiovascular Today, April 2020
COVID-19: Robotics may help to reduce exposure to virus patients during interventional procedures

ResearchGate, March 2020
Robotics For COVID-19: How Can Robots Help Health Care in the Fight Against Coronavirus?

WIRED, March 2020
The Covid-19 Pandemic Is a Crisis That Robots Were Built For

MEDICAL ROBOTICS REMAINS IN THE SPOTLIGHT

Medtronic Announces Acquisition of Digital Surgery to Accelerate Robot Assisted Surgery Strategy.
Globe Newswire, February 2020

Intuitive Surgical Acquires Orpheus Medical for Undisclosed Amount.
Globe Newswire, February 2020

Stryker Acquires Mobius Imaging and Cardan Robotics for $370 million upfront and up to $130 million of contingent payments correlated with development and commercial milestones.
Globe Newswire, September 2019

Corindus Vascular Robotics Announces Definitive Agreement to be Acquired by Siemens Healthineer for $1.1 billion
Business Wire, August, 2019

Johnson & Johnson Acquires Auris Health, Inc for $3.4 billion in cash. Additional contingent payments of up to $2.35 billion, in the aggregate, may be payable upon reaching certain predetermined milestones.
Globe Newswire, April 2019

Medtronic Acquires Mazor Robotics for $1.64 Billion.
PR Newswire, September 2018

EVOLUTION OF SURGERY

MULTIPLE OPPORTUNITIES – ENDOLUMINAL SURGERY



2020 KEY MILESTONES ACHIEVED

Strengthened Balance Sheet

Strengthened IP Portfolio:
38 Global Patents Issued/Allowed
19 Pending Patent Applications

Executed Pre-submission Meeting with the FDA Regarding the SCS

Unveiled First Ever Fully Disposable Robotic System

Bolstered Leadership Team:
Dr. Morag, CMO
Dr. Noa Ofer, IP/Regulatory

Recruited Thought Leaders to Enhance Core Capabilities:

- **Scientific Advisory Board:**
  Dr. Neeman, Dr. Yaniv, Dr. Wakhloo
- **Board of Directors:**
  Aileen Stockburger, Tal Wenderow


liberty
microbot medical

FULLY DISPOSABLE ROBOTIC SYSTEM

Eliminate Need for Capital Equipment

Operated Remotely

"One & Done" Capabilities

ANIMAL FEASIBILITY STUDY: OBJECTIVES

- Test the System in Peripheral and Neuro Procedures
- Evaluate Safety Measures
- Confirm Usability of the System with Leading KOL's



*The LIBERTY Robotic System is under its R&D phase, was not tested clinically and is not cleared for market within or outside the US

ANIMAL FEASIBILITY STUDY: MET PRIMARY ENDPOINTS

- Peripheral and Neuro Procedures Successfully Achieved
- No Intraoperative Adverse Effects
- Performed Flawlessly During Animal Study

liberty microbot medical

LIBERTY:
CLINICAL AND REGULATORY UPCOMING MILESTONES



SELF-CLEANING SHUNT (SCS): VENTRICULOPERITONEAL SHUNT MARKET OPPORTUNITY



SELF-CLEANING SHUNT (SCS): VENTRICULOPERITONEAL SHUNT MARKET OPPORTUNITY

- Hydrocephalus and Normal Pressure Hydrocephalus (NPH), are medical conditions in which there is an abnormal accumulation of cerebrospinal fluid (CSF) in the ventricles of the brain.
- Over 1,000,000 people in the United States currently live with hydrocephalus[1]



- The problem is often misdiagnosed as Dementia, Alzheimer's, or Parkinson's[2]
- NPH can cause dementia, difficulty in walking and urinary incontinence[2]

1. NIH, National Institute of Neurological Disorders and Stroke. http://www.ninds.nih.gov/disorders/hydrocephalus/detail_hydrocephalus.htm
2. National Hydrocephalus Foundation. http://nhfonline.org/facts-about-hydrocephalus.htm

SCS:
CLINICAL AND REGULATORY UPCOMING MILESTONES



ROBUST IP PLATFORM

PROVEN FOUNDERS

Prof. Moshe Shoham
Member of the Scientific Advisory Board

Prof. Moshe Shoham is a worldwide acclaimed authority in the field of robotics, conducting research in the robotic field for over the past 25 years, with a special focus on kinematics and dynamics of robots, sensor integration, multi-finger hands and medical applications.

- Founder of Mazor Robotics Ltd. acquired by Medtronic for $1.64B
- International Member, US National Academy of Engineering
- Head of the robotics lab at Technion's - Israel Institute of Technology - Faculty of Mechanical Engineering. Formerly the director of the robotic laboratory of the Department of Mechanical Engineering, Columbia University, NY.

Harel Gadot
CEO, President & Chairman

Mr. Harel Gadot was formerly a Worldwide Group Marketing Director at Ethicon Inc., a multi-billion dollar division of Johnson & Johnson company (NYSE: JNJ). Mr. Gadot was with J&J for a decade between 2000- 2010.

- Company Group Chairman for MEDX Ventures Group.
- Previously held leadership positions for Ethicon Inc. in Europe, Middle East and Africa.
- Served on the board of directors and led the business development for ConTIPI Ltd., an early stage medical device company, which was acquired by Kimberly Clark Corp (NYSE:KMB) in 2012.

Yossi Bornstein
Director

Mr. Yossi Bornstein is the President of Shizim Group, one of the leading MedTech eco-systems in Israel. He is a serial entrepreneur who played key roles in the healthcare industry over the past 35 years and is recognized for his activity both in Israel and internationally.

- He is a founder of multiple successful HealthCare companies and innovation centers, among them ShizimXL and ShizimVS.
- Previously he held the position of CEO at Bristol-Myers Squibb (BMS) in Israel.

PROVEN LEADERSHIP TEAM

Simon Sharon
Chief Technology Officer

Mr. Simon Sharon brings 23 years of R&D and general management in the medical devices space. Prior to Microbot Medical Mr. Sharon managed the R&D at Icecure Medical; an early stage, public medical device company. Mr. Sharon was the General Manager of Anorad Israel, a subsidiary of Rockwell Automation which manufactures sub-micron precision motion systems.

- Holds a B.Sc. from the Technion Institute of Technology and an M.Sc in Mechanical engineering from MIT where he specialized in motion control and Robotics.

Dr. Eyal Morag
Chief Medical Officer

Dr. Eyal Morag will lead the development and execution of the clinical strategy of the Company's technology platforms, including its current development of the Self-Cleaning Shunt (SCS) and LIBERTY products as well as its future pipeline.

- Member of the Company's Scientific Advisory Board since November 2017.
- Serves as Chairman of Radiology at Assuta Ashdod Medical Center, Ashdod, Israel.
- Recently served as the Regional Radiology Director at Mercy Health Partners Hospitals in Toledo, Ohio.
- Member of University Radiology Group (one of the largest private Radiology groups in the U.S.) where he headed the International Investment efforts for the Ventures division.

David Ben Naim
Chief Financial Officer

Mr. David Ben Naim is a CPA licensed in the State of Israel. Prior to joining Microbot Medical, Mr. Ben Naim operated DBN Financial.

- Previously served as CFO of Insuline Medical Ltd, a public company listed on the Tel-Aviv Stock Exchange (TASE:INSL).
- Prior to that Mr. Ben Naim served as CFO of Crow Technologies 1977 Ltd, a public company listed on the OTCQB (CRWTF), from 2008 – 2011.

SUMMARY

- Addressing multi-billion, high growth, underserved markets
- Developing micro-invasive medical robotic technology platforms to enhance clinician ability to treat patients with unmet medical needs
- Multi-generational product pipeline portfolio with robust launch cadence
- Significant IP creates barrier to entry
- Proven leadership team and continued involvement of founders, including Prof. Moshe Shoham, founder of Mazor Robotics
- Strong cash position to achieve meaningful milestones